Custom service
E. coli based VLP Production
Bacterial capsids — fast, cheap and engineered at the sequence level.
Bacterial VLP systems exploit capsids that self-assemble inside a cell: MS2 and Qβ single-stranded RNA phage capsids, hepatitis B core antigen, AP205. The host does the assembly; the engineer decides what the particle displays. Because the capsid gene is a bacterial gene and the system needs no post-translational modification, a construct can go from synthesis to assembled particle in three weeks, at yields bacterial expression is good at.
The classic use is antigen display for immunisation. A peptide or epitope fused to the coat protein is presented in hundreds of copies on the particle surface, which converts a poorly immunogenic peptide into a strong immunogen without a carrier protein — the particle is the carrier. Epitopes can be presented on the exterior surface through engineered insertion sites, or packaged inside as genetic cargo for delivery applications.
The limits are chemical, not biological. Disulfides, glycosylation and complex folding are absent, so displayed epitopes must be sequences that tolerate a bacterial cytoplasm. Cyclic and constrained peptides can be engineered with careful design, but a folded domain usually cannot. Where the epitope needs mammalian processing, the insect or mammalian VLP systems are the appropriate route.
Bacterial VLPs are the fast route to high-density peptide display for immunisation, to capsid-based assay reagents and standards, and to particles for packaging nucleic acid cargo in research contexts.
They cannot present folded domains or glycosylated epitopes, and particles intended for human use face regulatory expectations that bacterial endotoxin and host protein make harder to satisfy.
Batches are released with TEM morphology and count, intact capsid mass confirming the displayed insert, peptide mapping for display verification, endotoxin, and antigenicity against the displayed epitope. Insertion-site variants that failed assembly are documented in the campaign report.
Service Highlights
- Fast construct-to-particle. Three to five weeks from gene synthesis to purified capsid, the shortest timeline of any VLP system.
- High-density epitope display. 180 copies per particle for MS2/Qβ capsids, converting a weak peptide into a strong immunogen without a carrier.
- Several capsid platforms. MS2, Qβ, AP205 and HBc, with different particle sizes, stability and display chemistry.
- Interior and exterior loading. Epitopes on the surface through insertion sites; RNA, DNA or small molecules packaged inside.
- Display variants compared. Multiple insertion sites and linker lengths tested in one campaign to find the construct that displays without breaking assembly.
- Chemical conjugation option. Free cysteines or click handles engineered onto the capsid for post-assembly conjugation.
How the work runs
Capsid and insertion design
Platform chosen for particle size and stability; insertion site and linker designed against the epitope's structure.
Construct library
Two to six insertion variants cloned and expressed in parallel, since a bad insertion site breaks assembly.
Expression
E. coli culture with induction optimised for capsid assembly rather than soluble protein yield.
Purification
Lysis, clarification, nuclease treatment, and particle purification by SEC or density gradient.
Particle QC
TEM morphology, particle count, capsid mass by LC-MS, and display verification by peptide mapping.
Antigenicity
Binding to the displayed epitope measured by ELISA or SPR on the final particle.
Specifications & timeline
- Capsids
- MS2, Qβ, AP205, HBc; custom capsids on evaluation
- Display
- Exterior insertion or interior packaging; 180 copy number for MS2/Qβ
- Scale
- 1–10 L culture; 5–50 mg/L purified capsid
- QC
- TEM, LC-MS, display verification, antigenicity, endotoxin
- Timeline
- 3–5 weeks per construct
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.